Esonarimod

N/A

Report date: 2022/03/17 11:30:08
NME

Base Information

Drug NameEsonarimod
Drug Alias NameSonatimod艾那莫德esonarimodumesonarimodKE-298
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 alpha inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-1 alphaInterleukin-12 subunit beta
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaisho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaisho Pharmaceutical Holdings Co Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksKEGG